<DOC>
	<DOC>NCT02046603</DOC>
	<brief_summary>This open-label study will evaluate the efficacy and safety of RoActemra/Actemra (tocilizumab) as monotherapy or in combination with methotrexate or other non-biologic DMARDs in patients with active rheumatoid arthritis and an inadequate response to to current non-biologic DMARD therapy or the first anti-TNF agent. Patients will receive RoActemra/Actemra 162 mg subcutaneously weekly for 52 weeks.</brief_summary>
	<brief_title>A Study of RoActemra/Actemra (Tocilizumab) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Active rheumatoid arthritis according to the revised (1987) ACR criteria or EULAR/ACR (2010) criteria Patients who have an inadequate response to current nonbiologic DMARD therapy or the first antiTNF agent (in monotherapy or in combination with MTX or other nonbiologic DMARDs). Inadequate response to antiTNF treatment is defined as not achieving an adequate response to treatment at 24 weeks or after a minimum period of 12 weeks therapy if permitted by the local guidance, defined as DAS28 score improvement of less than 1.2 or patients achieving a DAS28 score improvement of 1.2 but not acheiving low disease activity (current DAS28ESR above 3.2) No previous exposure to RoActemra/Actemra (tocilizumab) Oral corticosteroids (&lt;/= 10 mg/day prednisone or equivalent) and nonsteroidal antiinflammatory drugs (NSAIDs; up to recommended dose) are permitted if on stable dose regimen for &gt;/= 4 weeks prior to baseline Permitted nonbiologic DMARDs are allowed if on stable dose for at least 4 weeks prior to baseline Receiving treatment on an outpatient basis, not including RoActemra/Actemra Females of childbearing potential and males with female partners of childbearing potential must agree to use reliable means of contraception as defined by protocol during the study and for at least 3 months following the last dose of RoActemra/Actemra Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following baseline Rheumatic autoimmune disease other than rheumatoid arthritis (RA) Functional Class IV as defined by the ACR Classification of Functional Status in Rheumatoid Arthritis Diagnosis of juvenile idiopathic arthritis or juvenile RA and/or RA before the age of 16 Prior history of or current inflammatory joint disease other than RA Exposure to tocilizumab either intravenous or SC at any time prior to baseline Treatment with any investigational agent within 4 weeks (or 5 halflives of the investigational drug, whichever is longer) of screening Intraarticular or parenteral corticosteroids within 4 weeks prior to baseline History of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies Known active current or history of recurrent infections Major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks of screening Active TB requiring treatment within the previous 3 years Positive for hepatitis B or hepatitis C virus infection Primary or secondary immunodeficiency (history of or currently active) Pregnant or lactating women Inadequate hematologic, renal or liver function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>